Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      One-pot multi-component synthesis of novel chromeno[4,3-b]pyrrol-3-yl derivatives as alpha - glucosidase inhibitors

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A green and efficient one-pot multi-component protocol was developed for the synthesis of some novel dihydrochromeno[4,3-b]pyrrol-3-yl derivatives through the reaction of arylglyoxals, malono derivatives, and different 4-amino coumarins in ethanol at reflux condition. In this method, all products were obtained in good to excellent yield. Next, all synthesized derivatives were evaluated for their α-glucosidase inhibitory activity. Most of the compounds displayed potent inhibitory activities with IC 50 values in the range of 48.65 ± 0.01–733.83 ± 0.10 μM compared to the standard inhibitor acarbose (IC 50 = 750.90 ± 0.14 μM). The kinetic study of compound 5e as the most potent derivative (IC 50 = 48.65 ± 0.01 μM) showed a competitive mechanism with a K i value of 42.6 µM. Moreover, docking studies revealed that dihydrochromeno[4,3-b]pyrrol-3-yl effectively interacted with important residues in the active site of α-glucosidase.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s11030-021-10337-w.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends

          The rising burden of type 2 diabetes is a major concern in healthcare worldwide. This research aimed to analyze the global epidemiology of type 2 diabetes. We analyzed the incidence, prevalence, and burden of suffering of diabetes mellitus based on epidemiological data from the Global Burden of Disease (GBD) current dataset from the Institute of Health Metrics, Seattle. Global and regional trends from 1990 to 2017 of type 2 diabetes for all ages were compiled. Forecast estimates were obtained using the SPSS Time Series Modeler. In 2017, approximately 462 million individuals were affected by type 2 diabetes corresponding to 6.28% of the world’s population (4.4% of those aged 15–49 years, 15% of those aged 50–69, and 22% of those aged 70+), or a prevalence rate of 6059 cases per 100,000. Over 1 million deaths per year can be attributed to diabetes alone, making it the ninth leading cause of mortality. The burden of diabetes mellitus is rising globally, and at a much faster rate in developed regions, such as Western Europe. The gender distribution is equal, and the incidence peaks at around 55 years of age. Global prevalence of type 2 diabetes is projected to increase to 7079 individuals per 100,000 by 2030, reflecting a continued rise across all regions of the world. There are concerning trends of rising prevalence in lower-income countries. Urgent public health and clinical preventive measures are warranted.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Natural Products for the Treatment of Type 2 Diabetes Mellitus.

            Type 2 diabetes mellitus is a metabolic disease characterized by persistent hyperglycemia. High blood sugar can produce long-term complications such as cardiovascular and renal disorders, retinopathy, and poor blood flow. Its development can be prevented or delayed in people with impaired glucose tolerance by implementing lifestyle changes or the use of therapeutic agents. Some of these drugs have been obtained from plants or have a microbial origin, such as galegine isolated from Galega officinalis, which has a great similarity to the antidiabetic drug metformin. Picnogenol, acarbose, miglitol, and voglibose are other antidiabetic products of natural origin. This review compiles the principal articles on medicinal plants used for treating diabetes and its comorbidities, as well as mechanisms of natural products as antidiabetic agents. Inhibition of α-glucosidase and α-amylase, effects on glucose uptake and glucose transporters, modification of mechanisms mediated by the peroxisome proliferator-activated receptor, inhibition of protein tyrosine phosphatase 1B activity, modification of gene expression, and activities of hormones involved in glucose homeostasis such as adiponectin, resistin, and incretin, and reduction of oxidative stress are some of the mechanisms in which natural products are involved. We also review the most relevant clinical trials performed with medicinal plants and natural products such as aloe, banaba, bitter melon, caper, cinnamon, cocoa, coffee, fenugreek, garlic, guava, gymnema, nettle, sage, soybean, green and black tea, turmeric, walnut, and yerba mate. Compounds of high interest as potential antidiabetics are: fukugetin, palmatine, berberine, honokiol, amorfrutins, trigonelline, gymnemic acids, gurmarin, and phlorizin.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update

                Bookmark

                Author and article information

                Contributors
                a_hasaninejad@yahoo.com
                Journal
                Mol Divers
                Mol Divers
                Molecular Diversity
                Springer International Publishing (Cham )
                1381-1991
                1573-501X
                25 October 2021
                : 1-13
                Affiliations
                [1 ]GRID grid.412491.b, ISNI 0000 0004 0482 3979, Department of Chemistry, Faculty of Sciences, , Persian Gulf University, ; 7516913817 Bushehr, Iran
                [2 ]School of Chemistry, College of Science, Uccniversity of Tehran, P.O.Box, 14155-6455 Tehran, Iran
                [3 ]GRID grid.412571.4, ISNI 0000 0000 8819 4698, Stem Cells Technology Research Center, , Shiraz University of Medical Sciences, ; Shiraz, Iran
                [4 ]GRID grid.412571.4, ISNI 0000 0000 8819 4698, Central Research Laboratory, , Shiraz University of Medical Sciences, ; Shiraz, Iran
                [5 ]GRID grid.411705.6, ISNI 0000 0001 0166 0922, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, , Tehran University of Medical Sciences, ; P.O. Box 14155-6451, 1417614411 Tehran, Iran
                [6 ]GRID grid.411705.6, ISNI 0000 0001 0166 0922, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, , Tehran University of Medical Sciences, ; Tehran, Iran
                Author information
                http://orcid.org/0000-0003-0002-1373
                Article
                10337
                10.1007/s11030-021-10337-w
                8544188
                34697701
                3d1f1f81-796e-4694-bd18-be4d50b0c60c
                © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 2 August 2021
                : 6 October 2021
                Categories
                Original Article

                Molecular biology
                chromeno[4,3-b]pyrrol,α-glucosidase inhibitor,multi-component reactions,molecular docking,synthesis

                Comments

                Comment on this article